CLOs on the Move

Motif Neurotech

www.motifneuro.tech

 
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

VeriChip Corporation

VeriChip Corporation is a Delray Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedTec

MedTec is a Hillsborough, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIOCARDIA

BIOCARDIA is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

LumiThera

At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.

AbsoluteCare

We are passionate about our work and compassionate toward our people, whether they work here or seek care from us. We opened the first AbsoluteCare center in Atlanta in 2000, with a primary focus on treating members with HIV/AIDS. We quickly became an HIV Center of Excellence, achieving impressive results: an 88 percent retention rate and a 97 percent undetectable rate. A surprising thing happened. With so many of them free of the symptoms of HIV/AIDS, our members sought primary care from us. They were coming in for help controlling asthma, diabetes, heart disease, hypertension, and all the other conditions that life and aging had thrown their way. So we transformed. We assembled a larger team of qualified, passionate practitioners to offer whole-life care in a new, larger center. And in the last two decades, we have expanded our facilities to multiple locations in several states, where we offer our members everything from primary care to nutrition counseling, behavioral health, and life services. The members who set foot in an AbsoluteCare center are usually underserved. With their health already compromised, life`s daily stressors add to their level of need.